ReviewCurrent pain and headache reports2014
Drug combinations in the treatment of neuropathic pain.
Review in Current pain and headache reports, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 40 citations in OpenAlex.
- Platelet-rich Plasma for the Treatment of Neuropathic Pain: A Systematic Review.Current drug research reviews · 2025Pooled it
- Research trends and hotspots of neuropathic pain in neurodegenerative diseases: a bibliometric analysis.Frontiers in immunology · 2023Pooled it
- Oromucosal Administration of a Cannabidiol-Enriched Cannabis sp. Extract for 2 Weeks Moderately Reduces Cold Hyperalgesia in Rats With Neuropathic Pain.European journal of pain (London, England) · 2026Article
- Phenylephrine per se or Combined with Pregabalin Ameliorates Mononeuropathic Pain in Rats.Pharmaceutics · 2026Article
- Evaluating the Antihyperalgesic Potential of Sildenafil-Metformin Combination and Its Impact on Biochemical Markers in Alloxan-Induced Diabetic Neuropathy in Rats.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Combination Drug Therapy for the Management of Chronic Neuropathic Pain.Biomolecules · 2023Review
- Genomic Interplay between Neoneurogenesis and Neoangiogenesis in Carcinogenesis: Therapeutic Interventions.Cancers · 2023Review
- Combination Therapy for Neuropathic Pain: A Review of Recent Evidence.Journal of clinical medicine · 2021Review
- Article
- Transplantation of Mesenchymal Stromal Cells Expressing the Human Preproenkephalin Gene Can Relieve Pain in a Rat Model of Neuropathic Pain.Neurochemical research · 2020Article
- Tumor-induced neurogenesis and immune evasion as targets of innovative anti-cancer therapies.Signal transduction and targeted therapy · 2020Review
- Interleukin-1beta in synergism gabapentin with tramadol in murine model of diabetic neuropathy.Inflammopharmacology · 2019Article
- Pharmacotherapy for Neuropathic Pain: A Review.Pain and therapy · 2017Review
- Analgesic Properties of Opioid/NK1 Multitarget Ligands with Distinct in Vitro Profiles in Naive and Chronic Constriction Injury Mice.ACS chemical neuroscience · 2017Article
- Nortriptyline Enhances Morphine-Conditioned Place Preference in Neuropathic Rats: Role of the Central Noradrenergic System.Anesthesia and analgesia · 2017Article
- The need for new approaches in CNS drug discovery: Why drugs have failed, and what can be done to improve outcomes.Neuropharmacology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pharmacotherapy, the main treatment option for neuropathic pain, remains a major clinical challenge. The most commonly studied drug classes in the context of neuropathic pain-antidepressants, anticonvulsants, and opioids-have only limited efficacy and frequent dose-limiting adverse effects. Yet, most guidelines recommend monotherapy as the first line of neuropathic pain treatment. Recent understanding of neuropathic pain pathophysiology suggests that multiple mechanisms, both at the peripheral and the central nervous system levels, underlie neuropathic pain, pointing to the possibility that targeting multiple mechanisms simultaneously can improve treatment outcome. A few clinical trials using various drug combinations for neuropathic pain have already been published but yielded inconsistent results, partially due to methodological problems associated with the conduction of such trials. Nonetheless, combination therapy remains an intriguing treatment option for neuropathic pain, awaiting future high-quality validating trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.